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withdrawn in patient 1 and reduced (budesdonide from 15 to
5mg) in patient 2. Mononuclear cells were analyzed by ﬂow
cytometry before and after IL-2 in patients and healthy
donors. Treg subsets were determined within the CD4+ T cell
population to identify thymus-derived natural Treg (nTreg)
and induced Treg (iTreg). NK cell subsets were determined
within CD56+CD3- population to identify CD56bright,
CD56dimNKG2A+KIR-, and CD56dim KIR+CD57+ NK cells.
Functional analysis was performed by isolating Treg
(CD3+CD4+CD25hiCD127dim), conventional T cells (Tcon:
CD3+CD4+CD25loCD127hi) and NK cells (CD3-CD56+). Treg
function was measured by suppression of CD154 expression
on Tcon stimulated with CD3/CD28 beads. NK cell function
was measured by K562 killing. Healthy volunteers showed
a signiﬁcant increase in both nTreg and iTreg by 2-3 fold
(p¼0.0003) and CD56bright NK cells by 1.2-1.8 fold in 7 days
after the initial dose of IL-2 (p¼0.02). In patients, the fraction
of nTreg increased above baseline by 1.2-1.4 fold while iTreg
decreased. NK cells showed marked expansion of CD56bright
NK cells within 2 weeks of treatment, with no change in
CD56dimNKG2A+KIR-, and CD56dimKIR+CD57+ NK cells.
Functional assays demonstrated increased Treg suppression
of autologous Tcon and NK cell killing of K562 after IL-2
treatment in both patients. These ﬁndings indicate that ultra
low dose IL-2 causes expansion of natural Treg and NK cells
resulting in greater suppressive activity and K562 killing
activity correlating with an improvement in cGVHD for
steroid refractory patients.
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The favorable outcome of umbilical cord blood trans-
plantation (UCBT) is compromised by prolonged time to
engraftment, delayed immunologic reconstitution and late
memory T cell skewing. Studies in zebraﬁsh and mice have
shown that the prostaglandin compound, 16,16 dimethyl
prostaglandin E2 (PGE2) increases HSC engraftment. We
performed a Phase Ib clinical trial of double UCBT (dUCBT)
using one untreated and one ex vivo PGE2-treated UCB unit
to determine safety and engraftment. 12 subjects with
hematologic malignancies were enrolled. The PGE2-UCB was
the dominant source of hematopoiesis in 10 of 12 subjects
with full T cell chimerism detected as early as 13 days. In UCB
T cells, PGE2 mediated increase of intracellular cAMP, acti-
vation of PKA and modulated the Wnt/b-catenin pathway as
determined by upregulation of b-catenin and expression of
Wnt target genes Lef1, Tcf7 and Runx1. PGE2 inhibited
proliferation of UCB T cells in response to stimulation via
CD3/CD28 and resulted in high expression of IL-7 receptor
(CD127). Assessment of T cell reconstitution indicated that
during the ﬁrst year, the numbers of total T cells (CD3+), CD4+
and CD8+ T subsets remained signiﬁcantly lower (p¼0.036)
in PGE2-UCBT recipients compared to dUCBT recipients
without PGE2. To examine whether PGE2-mediated Wnt/b-
catenin imprinting might be evident in PGE2-UCBT recipi-
ents, we examined expression of the Wnt/b-catenin target
Eomes, a transcription factor that links the long-term
memory CD8+ T cells to effector potency and protective
immunity. Expression of Eomes was signiﬁcantly elevated in
PBMCs of PGE2-UCBT recipients compared to controls.
Consistent with the role of Wnt/b-catenin to maintain
a central memory/stem cell memory CD8+ phenotype, there
was an increased fraction of CD8+CD62L+ cells in recipients of
PGE2-UCBT in contrast to the late memory T cell skewing in
dUCBT recipients without PGE2. Moreover, PGE2-UCBT
recipients displayed potent antiviral immunity resulting in
a reduced incidence of CMV viremia and no EBV-mediated
posttransplant lymphoproliferative disorder. Our ﬁndings
indicate that PGE2-UCB treatment induces Wnt-mediated
gene programming and might favor the generation of long-
lived memory CD8+ T cells.71
Impaired B Cell Clonotype Diversiﬁcation After
Allogeneic Hematopoietic Cell Transplantation Predicts
Graft-Versus-Host Disease
Aaron Logan 1, Bita Sahaf 1, Bing Zhang 2, Sally Arai 1,
Victoria Carlton 3, Jianbiao Zheng 3, Martin Moorhead 3,
Mark R. Krampf 1, Carol D. Jones 2, Amna N. Waqar 2,
Malek Faham3, Judith A. Shizuru 1, James L. Zehnder 2,
David B. Miklos 1. 1 Dept. of Medicine, Div. of Blood and Marrow
Transplantation, Stanford University School of Medicine,
Stanford, CA; 2Dept. of Pathology, Stanford University School of
Medicine, Stanford, CA; 3 Sequenta, Inc., South San Francisco, CA
Graft-versus-host disease (GVHD) is a detrimental
complication of allogeneic hematopoietic cell trans-
plantation (HCT) associatedwith impaired quality-of-life and
decreased overall survival. Methods for predicting GVHD
may enable use of pre-emptive therapeutic maneuvers to
prevent or diminish clinical GVHD symptoms. Studies of
GVHD in murine allograft models have shown that GVH
reactions are associated with structural and functional
derangements of lymphoid tissues, including lymph nodes,
spleen, thymus, and bone marrow. Because these organs
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ﬁndings suggest that GVHD, even in sub-clinical stages, may
impair diversiﬁcation of the immune repertoire. We evalu-
ated post-HCT B cell immunoglobulin heavy chain (IGH) gene
diversity in 42 patients with chronic lymphocytic leukemia
who received unmanipulated mobilized peripheral blood
grafts following total lymphoid irradiation and anti-thymo-
cyte globulin (TLI/ATG). Twenty-one patients also received 4
weekly doses of Rituximab beginning 2 months post-HCT.
Post-HCT peripheral blood samples were prospectively
archived at pre-scheduled intervals. The IGH repertoire was
quantiﬁed in over 400 samples using the LymphoSIGHT(TM)
method, which employs consensus IGH V and J segment
primers to universally amplify rearranged IGH genes, fol-
lowed by massively parallel high-throughput sequencing
(IGH-HTS) and bioinformatic analysis. Donor graft material
was analyzed in the same manner. A median 1.8x10e6
(2.6x10e4 e 2.7x10e6) leukocyte genomes per sample with
a median 6.4x10e5 (12 e 7.6x10e5) IGH molecules were
analyzed. Compared to healthy donors, patients receiving
only TLI/ATG exhibited signiﬁcantly decreased diversity at
days +30 and +90 (p<0.001) (Figure 1A), whereas IGH
diversity remained signiﬁcantly decreased at days +30, +90,
+180, +270 (each P < .001) and +365 (p<0.05) in those who
received post-HCT Rituximab (Figure 1B). Clonotype analysis
conﬁrmed signiﬁcant (p¼0.009) but incomplete depletion of
adoptively transferred IGH clones in those receiving post-
HCT Rituximab (Figure 1C). The incidences of relapse (38 vs.
52%) and new-onset GVHD (28 vs. 33%) were similar in the
two groups. Amongst patients at risk for new onset GVHD
(after censoring for relapse and Rituximab treatment), IGH
diversity was signiﬁcantly decreased at day +30 (54 +/- 13 vs.
18818 +/- 11576 unique IGH clones; P ¼ .03) and day +90
(2693 +/- 2657 vs. 40316 +/- 16480 unique IGH clones; P ¼
.02) in those who subsequently developed GVHD in
comparison to those who did not (Figure 1D). IGH-HTS
analysis of the adoptively transferred and reconstituting B
cell repertoires after allo-HCT may provide a method for
predicting new onset GVHD and for identifying pathogeni-
cally involved adoptively transferred B cell clones.
Figure 1. Box and whisker plots demonstrating post-HCT IGH clonotypc
diversity in the peripheral blood of patients allografted after conditioning with
TLI/ATG (A) or TLI/ATG + post-HCT Rituximab (B). Mean (+s.e.m.) number of
adoptively transferred IGH elonotypes in patients conditioned with TLI/ATO
(solid line) or TLJ/ATG Riluximab (dotted line) (C). IGH clonotype diversity at
days +30 and +90 post-HCT in patients who did (GVHD+; red) or did not (No
GVHD; black) subsequently develop GVHD) after censoring for relapse,
Riluximab treatment, and prior GHVD (D). Numbers on graph indicate
evaluable patients at each time point.72
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Umbilical cord blood transplantation (UCBT) is increas-
ingly used as an alternative source for allogeneic hemato-
poietic stem cell transplantation. A signiﬁcant component of
immune reconstitution after UCBT involves thymic regen-
eration, which can be measured by T-cell receptor rear-
rangement excision circles (TRECs). TREC levels are a strong
predictive factor for overall survival in adult recipients of
UCBT. Injury of the thymic microenvironment, particularly
of thymic epithelial cells (TEC), during HSCT compromises
thymopoiesis. Human UCB is enriched in endothelial
precursors that can sustain thymopoiesis in immunodeﬁ-
cient mice transplanted with human thymic grafts, where
they engraft and promote neovascularization and wound
healing. We examined markers of angiogenesis and neo-
vascularization ANG1 and VEGF associated with TEC func-
tion, thymic regeneration and T cell reconstitution in
patients after double reduced intensity UCBT. 27 evaluable
patients with a median age of 50 years with hematopoietic
malignancies were treated with (Flu/Mel/rATG) condi-
tioning followed by double UCBT; GvHD prophylaxis was
tacrolimus and sirolimus. At various time points Which ones
after UCBT, serum levels of IL-7 and SCF that are produced
by TEC displayed a strong correlation (p<0.005) with ANG1
and VEGF indicating that functional recovery of TEC is
associated with angiogenesis and neovascularization. In
contrast, serum levels of IL-7 and SCF displayed a strong
inverse correlation (p<0.001) with TREC, CD4+, CD8+ and
Treg numbers suggesting that uptake of these cytokines by
cognate IL-7R and Kit receptor on immature T cell progen-
itors resulted in their differentiation and expansion. IL-7
and SCF also displayed a strong inverse correlation
(p<0.001) with the ability of T cells to differentiate into
pathogen-speciﬁc effectors as determined by CMV-speciﬁc
IFN-g ELISpot. Conversely, VEGF and ANG1 levels positively
correlated (p<0.001) with CD4+, CD4+CD25+ and
CD4+CD45RA+ numbers. Our results are consistent with
a model in which ANG1 and VEGF support TEC recovery
leading to production of SCF and IL-7 by TEC and uptake of
these cytokines by T cell progenitors resulting in their
differentiation and expansion. These sequential steps in the
process of thymic regeneration might represent novel
therapeutic targets for improvement of immune reconsti-
tution after UCBT.
